Last updated on: 19 October 2026|Author: 2 Kapseln Bitte

Blood Sugar & Metabolic Health

Q: Turmeric for metabolic syndrome?

Meta-analyses in metabolic syndrome report partly better fasting glucose, HDL and diastolic blood pressure with curcumin; for triglycerides and waist circumference the results are inconsistent [4, 5]. Curcumin does not replace medical treatment.

Free text search

Meta-analyses report on average lower HbA1c and fasting glucose with curcumin in type 2 diabetes, but the studies are described as inconsistent [4, 5]. Curcumin is no substitute for medical therapy.

Short answer

Meta-analysis: in type 2 diabetes HbA1c on average −0.5% and fasting glucose −11.7 mg/dL
The evidence is described as inconsistent; studies are small and short
9-month study in prediabetes: no diabetes in the curcumin group, 16.4% on placebo
Interactions with antidiabetic drugs are possible; medical clarification is needed

What's behind it

Curcumin is being studied in type 2 diabetes and prediabetes both mechanistically and in clinical trials. The mechanistic evidence comes from cell and animal studies: in muscle cells, curcumin activated AMPK and increased glucose uptake [1]; in mouse muscle cells the finding was consistent with GLUT4 translocation to the cell surface [2]; in rats it improved glucose tolerance via increased GLP-1 release [3]. These studies do not show whether the mechanisms transfer to humans.

What the sources show

Meta-analyses. A 2018 meta-analysis of 11 placebo-controlled trials in adults found that turmeric extract, curcuminoids or curcumin lowered fasting glucose by 8.9 mg/dL and HbA1c by 0.54 percentage points on average; HOMA-IR did not change, and there was no effect on fasting glucose in people without impaired glucose regulation [4]. An overview of 22 meta-analyses (to January 2024) reports lower fasting blood sugar, HbA1c, HOMA-IR and insulin, with partly high heterogeneity [5]. A meta-analysis of 103 RCTs rates the evidence for fasting blood sugar as high but points to methodological limitations of the studies [6].

Individual studies in type 2 diabetes. In 100 people, fasting glucose, HbA1c and HOMA-IR fell versus placebo on 300 mg curcuminoids per day over 3 months [7]. In 100 people on standard care, after 3 months of 500 mg curcuminoids plus 5 mg piperine, glucose, C-peptide and HbA1c were lower; hs-CRP did not differ [8].

Prediabetes. In a 9-month study of 240 people with prediabetes, one group received curcumin capsules. No one in that group was diagnosed with type 2 diabetes, versus 16.4% in the placebo group [9]. This is the finding of a single study and no evidence of a general preventive effect.

What this means in practice

The studies differ in product, dose (here 300–500 mg curcuminoids per day in the individual studies) and duration (3 to 9 months); no dosing recommendation follows from them. A case report discusses possible hypoglycaemia under curcumin plus piperine in a patient with a previously unrecognised insulinoma; the link is a hypothesis of the authors [10]. If you use antidiabetic drugs or insulin, discuss any supplement with your treating practice beforehand. More at safety and side effects.

Limits of the statement

The authors of the 2018 meta-analysis report high heterogeneity between studies and evidence of publication bias [4]. The individual studies are small and of limited duration, and products and doses differ widely. For type 1 diabetes the sources contain no data. On the regulatory side, EFSA assessed a health claim application on curcumin and joint function in 2017 and did not consider a cause-and-effect relationship established [11]. We are not aware of authorised health claims on blood sugar or diabetes. This answer does not replace medical advice.

Common follow-up questions

No. In the studies, curcumin was given on top of ongoing treatment, not instead of it: in a study in type 2 diabetes, HbA1c (−0.9% vs −0.2% with placebo) and glucose fell more than with placebo after 3 months of standard care plus 500 mg curcuminoids with piperine (Panahi et al., 2018) DOI. A meta-analysis found an average HbA1c reduction of 0.54 percentage points for curcuminoids, with high heterogeneity and evidence of publication bias (de Melo et al., 2018) DOI. Because effects can add to those of medication, medical advice is needed before taking it.

It depends on the study. The meta-analysis included trials with at least 4 weeks of follow-up and found an average fasting glucose reduction of about 9 mg/dL, with high heterogeneity (de Melo et al., 2018) DOI. In type 2 diabetes, fasting glucose and HbA1c were lower than with placebo after 3 months of 500 mg curcuminoids plus piperine (Panahi et al., 2018) DOI. The prediabetes study ran for 9 months with measurements at 3, 6 and 9 months (Chuengsamarn et al., 2012) DOI.

Amounts and preparations varied: 500 mg curcuminoids with 5 mg piperine per day for 3 months in type 2 diabetes (Panahi et al., 2018) DOI, 1,100 mg curcumin per day for 3 months (Nada et al., 2025) DOI and a phytosome preparation with 200 mg curcumin per day for 8 weeks in overweight people (Cicero et al., 2020) DOI. These are study doses, not a recommendation; agree on an individual dose with your doctor.

We found no studies in humans on this. The type 1 hits in our search are animal studies, for example in diabetic rats (Naghdi et al., 2022) DOI. People with type 1 diabetes need insulin to survive (WHO). Talk to your diabetes team before taking any supplement.

A meta-analysis of 11 randomized trials (at least 4 weeks, adults) found a reduction in fasting blood glucose of about 8.9 mg/dL with turmeric, curcuminoids or curcumin; it was seen in people with impaired glucose regulation, not in non-diabetic people. Heterogeneity was high and there was evidence of publication bias (de Melo et al., 2018) DOI. A larger meta-analysis of 103 trials rated the certainty of evidence for changes in fasting blood sugar as high, but pointed to methodological limitations of the trials (Jafari et al., 2024) DOI.

What's behind it

HOMA-IR is used in studies as an index of insulin resistance [1]. Mechanistic work on curcumin comes exclusively from cell and animal studies. In rat muscle cells (L6), curcumin activated AMPK and increased glucose uptake; in mice it raised AMPK phosphorylation in skeletal muscle [2]. In mouse muscle cells (C2C12), curcumin induced glucose uptake and AMPK phosphorylation, but not the PI3K/Akt pathway; together with insulin both pathways were enhanced, consistent with GLUT4 translocation to the cell surface [3]. In diabetic rats, curcumin improved glucose and insulin tolerance [4]. In rats, curcumin (1.5 mg/kg) improved glucose tolerance via increased GLP-1 and insulin secretion [5]; in mice on a high-fat diet it attenuated the development of insulin resistance [6].

What the sources show

Meta-analyses. An overview of 22 meta-analyses reports lower HOMA-IR, fasting insulin, fasting blood glucose and HbA1c with curcumin, with moderate to high heterogeneity [7]. A meta-analysis of 103 RCTs rates the evidence for insulin and HOMA-IR as moderate and for fasting blood sugar as high [8]. In people with NAFLD (21 RCTs), HOMA-IR was lower, but plasma fasting insulin did not change significantly [9].

Individual studies. In 240 people with prediabetes, HOMA-IR after 9 months of curcumin was 3.22 versus 4.04 on placebo [1]. In 100 people with type 2 diabetes, fasting glucose, HbA1c and HOMA-IR fell on 300 mg curcuminoids per day over 3 months [10]. In 100 people with type 2 diabetes on standard care, after 3 months of 500 mg curcuminoids plus 5 mg piperine, glucose, C-peptide and HbA1c were lower than on placebo [11]. In 80 overweight people with borderline fasting glucose, 800 mg of a phytosome product (200 mg curcumin) over 8 weeks improved fasting insulin versus placebo; the HOMA index improved versus baseline [12].

What this means in practice

The studies differ in target group, product, dose (300–800 mg per day in the individual studies named here) and duration (8 weeks to 9 months); no dosing recommendation can be derived from them. Curcumin replaces neither insulin nor prescribed medication. A case report discusses possible hypoglycaemia under curcumin plus piperine in a patient with a previously unrecognised insulinoma; the link is a hypothesis of the authors [13]. If you use glucose-lowering medication or insulin, discuss any supplement with your treating practice beforehand. More at safety and side effects.

Limits of the statement

The mechanisms were shown in cells and animals, not in humans. The meta-analyses are heterogeneous, the individual studies small. For type 1 diabetes the cited sources contain no data. This text describes studies and makes no health promises.

Common follow-up questions

No. In the study, curcumin was given on top of standard treatment and dietary advice (500 mg curcuminoids with 5 mg piperine per day, 3 months), not instead of it; HbA1c and glucose fell more than with placebo (Panahi et al., 2018) DOI. In another study, too, curcumin was added to ongoing glimepiride (Nada et al., 2025) DOI. Discuss any change to tablets or insulin only with your care team.

That is a medical decision that may only be made together with your treating doctor. In the study, participants stayed on their standard treatment; curcumin was added, and reducing medication was not part of the investigation (Panahi et al., 2018) DOI. Whether your insulin requirement changes is therefore not shown and must be medically supervised.

In a study in overweight people with slightly elevated fasting glucose, fasting insulin was lower than with placebo after 8 weeks and the HOMA index was lower than at baseline (Cicero et al., 2020) DOI. In the prediabetes study, HOMA-IR was lower in the curcumin group than with placebo after 9 months (Chuengsamarn et al., 2012) DOI. The time frames therefore differ between studies.

We found no separate study data on this. The meta-analysis found reductions in fasting glucose in people with some degree of dysglycemia but not in non-diabetic individuals; baseline glucose was an important covariate and heterogeneity was high (de Melo et al., 2018) DOI. No statement on severe insulin resistance can be derived from this; a medical assessment is sensible.

There is no evidence for that. People with type 1 diabetes need insulin to survive (WHO). We found no human studies of curcumin in type 1 diabetes; the hits come from animal experiments, for example in diabetic rats (Naghdi et al., 2022) DOI.

What's behind it

In non-alcoholic fatty liver disease (NAFLD), excess fat accumulates in liver tissue, which can lead to oxidative and inflammatory damage [1]. Evidence on mechanisms for curcumin comes mainly from animal work: in mice on a high-fat diet it inhibited lipogenic gene expression in the liver and inflammatory processes in adipose tissue [2]. A review describes that curcumin modulates transcription factors and cytokines, but names its limited oral bioavailability as a constraint [3].

What the sources show

Metabolic values. A meta-analysis of 21 RCTs with 1,191 people with NAFLD (curcumin 50–3,000 mg/day) found lower fasting glucose, HOMA-IR, triglycerides, total and LDL cholesterol, as well as slightly lower body weight and BMI. HbA1c, insulin, HDL, CRP and TNF-α did not change significantly. The authors point to risks of bias and missing analyses of the products tested [4].

Liver enzymes: inconsistent. One meta-analysis of 14 studies reports lower ALT and AST, with very high heterogeneity [5]. Another with 15 studies (n = 835) found no effect on ALT but lower AST; longer interventions and higher doses per kilogram of body weight went along with smaller effects [6]. A third with 14 studies found no significant effect on either ALT or AST, but lower triglycerides and a smaller waist circumference [7].

Liver fat on ultrasound. A meta-analysis of 16 RCTs (1,028 participants) reports more frequent resolution of steatosis on ultrasound (RR 3.96) [8]. In one RCT with 1,000 mg phytosomal curcumin per day for 8 weeks (87 completers; all participants received dietary and lifestyle advice), the ultrasound finding improved in 75.0% versus 4.7% on placebo [1].

Individual studies. In a pilot study (250 mg/day, 8 weeks, 44 people analysed), promoter methylation of the repair genes MLH1 and MSH2 was lower; the DNA damage marker 8-OHdG and liver enzymes did not change [9]. In 65 people with NAFLD, phytosomal curcumin raised adiponectin, lowered leptin, and HDL was higher than on placebo [10]. A study in overweight people with borderline fasting glucose, i.e. not people with NAFLD, found better transaminases and a better fatty liver index than placebo with 800 mg of a phytosome product (200 mg curcumin) over 8 weeks [11].

What this means in practice

The studies used very different products, doses (50–3,000 mg/day) and durations. The results therefore cannot be transferred to a single product, and no dosing recommendation follows from them. Curcumin replaces neither medical work-up nor treatment of a fatty liver. If you want to take curcumin supplements, discuss it with your doctor first. More at safety and side effects.

Limits of the statement

The meta-analyses are strongly heterogeneous, the individual studies small and short. For liver cirrhosis there is a pilot RCT with 70 patients (1,000 mg/day, 3 months) in which severity scores (MELD, Child-Pugh) fell [12]. It is too small to draw conclusions for use. Whether the findings transfer to other liver diseases is not established.

Common follow-up questions

Yes, in one small study; a lasting benefit for patients is not shown. In a randomized pilot trial of 70 patients (1,000 mg curcumin per day, 3 months), the severity scores MELD and Child-Pugh were lower after treatment than with placebo (Nouri-Vaskeh et al., 2020) DOI. These scores estimate disease severity; whether this translates into a benefit for patients was not studied. Liver cirrhosis requires medical care.

In a randomized trial in 70 people with liver cirrhosis (1,000 mg curcumin per day), the severity scores MELD, MELD-Na and Child-Pugh fell in the curcumin group after 3 months while they rose in the placebo group; the authors call it a pilot study (Nouri-Vaskeh et al., 2020) DOI. In overweight people with impaired fasting glucose, transaminases and the fatty liver index were lower than with placebo after 8 weeks of a phytosome preparation (Cicero et al., 2020) DOI.

Study doses differ: 1,000 mg curcumin per day in two doses for 8 weeks in NAFLD (Panahi et al., 2016) DOI; a phytosome preparation with 200 mg curcumin per day for 8 weeks in overweight people (Cicero et al., 2020) DOI. The meta-analysis of 21 trials (1,191 people with NAFLD) covered doses of 50–3,000 mg per day (Ebrahimzadeh et al., 2024) DOI. These are study doses, not a recommendation; discuss the dose with your doctor.

Want to dive deeper into the subject? Continue here:

Bioavailability: Understand the mechanisms of absorption and why bioavailable formulations are decisive.
Safety check: The full safety profile and important information on side effects and interactions.
Effects guide: A broad overview of the therapeutic application areas and all the benefits of curcumin.

References

[1] Panahi, Y. et al. (2017). Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug Research. DOI: 10.1055/s-0043-100019
[2] Shao, W. et al. (2012). Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE. DOI: 10.1371/journal.pone.0028784
[3] Ghosh, S. et al. (2015). The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food and Chemical Toxicology. DOI: 10.1016/j.fct.2015.05.022
[4] Ebrahimzadeh, A. et al. (2024). Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized clinical trials. Complementary Therapies in Medicine. DOI: 10.1016/j.ctim.2024.103025
[5] Ebrahimzadeh, A. et al. (2025). Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized clinical trials. Food Science & Nutrition. DOI: 10.1002/fsn3.4144
[6] Aragón-Vela, J. et al. (2024). Does curcumin improve liver enzymes levels in nonalcoholic fatty liver disease? A systematic review, meta-analysis, and meta-regression. Phytotherapy Research. DOI: 10.1002/ptr.8274
[7] Malik, A. S. & Malik, M. (2024). Effects of curcumin in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Canadian Liver Journal. DOI: 10.3138/canlivj-2023-0022
[8] Ngu, M. H. et al. (2022). Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: a systematic review and meta-analysis. Complementary Therapies in Medicine. DOI: 10.1016/j.ctim.2022.102843
[9] Hariri, M. et al. (2020). A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled, clinical trial. Complementary Therapies in Medicine. DOI: 10.1016/j.ctim.2020.102447
[10] Mirhafez, S. R. et al. (2019). Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial. Journal of Gastrointestinal and Liver Diseases. DOI: 10.15403/jgld-179
[11] Cicero, A. F. G. et al. (2020). Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. European Journal of Nutrition. DOI: 10.1007/s00394-019-01916-7
[12] Nouri-Vaskeh, M. et al. (2020). Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phytotherapy Research. DOI: 10.1002/ptr.6620

A meta-analysis of 64 RCTs reports slightly lower triglycerides on average with curcumin (−6.7 mg/dL); the evidence is rated low to very low [5]. In metabolic syndrome the results are inconsistent [10, 11].

In short

Meta-analysis (64 RCTs): on average −6.7 mg/dL triglycerides, evidence low to very low
In NAFLD: meta-analyses with lower triglycerides
In metabolic syndrome: inconsistent results
Mechanisms come from cell and animal studies

What's behind it

Raised triglycerides are among the criteria of the metabolic syndrome, a cluster of risk factors for cardiovascular disease and type 2 diabetes [1]. Evidence on mechanisms comes from animal and cell studies: in mice on a high-fat diet, curcumin lowered lipogenic gene expression in the liver [2]. In hamsters on a high-fat diet (0.05 g curcumin per 100 g diet), triglycerides in plasma and liver were lower, hepatic fatty acid oxidation higher and fatty acid synthase activity lower [3]. In liver cells (HepG2), curcumin reduced oleic-acid-induced lipid accumulation, lowered SREBP-1 and fatty acid synthase, and increased AMPK phosphorylation and PPAR-α expression [4]. These studies do not show whether the same happens in humans.

What the sources show

General meta-analysis. In 64 RCTs, triglycerides were on average 6.69 mg/dL lower with curcumin/turmeric (WMD), as were total and LDL cholesterol; HDL was 1.80 mg/dL higher. The authors rate the evidence as low to very low and call for caution [5].

NAFLD. In 21 RCTs in people with NAFLD, triglycerides were on average 10.31 mg/dL lower [6]. Another meta-analysis (14 studies) also found lower triglycerides (−13.22) but no significant changes in the other blood lipids [7].

Individual studies. In a crossover study of 30 obese people, 1 g curcuminoids per day for 30 days significantly lowered triglycerides; total, LDL and HDL cholesterol and hs-CRP were unchanged [8]. In healthy middle-aged people (n = 38), triglycerides were lower after 4 weeks on 80 mg/day of a lipidated curcumin, without a rise in CRP [9].

Metabolic syndrome: inconsistent. One meta-analysis of 7 RCTs reports significantly better triglycerides [10], a more recent one with 13 RCTs (785 participants) no significant change (MD 1.28) [11].

What this means in practice

Relative to the scatter between studies, the effects are small and depend on product, dose (80 mg to 1 g per day in the individual studies) and population. The cited sources did not compare curcumin with triglyceride-lowering drugs, so they are no yardstick for a replacement. Raised blood lipids belong in medical care. More on tolerability at safety and side effects.

Limits of the statement

The large meta-analysis itself rates its evidence as low to very low [5]; in NAFLD heterogeneity is high (I² 84.5%) [6]. The individual studies are small and short (30 days to 4 weeks). The mechanisms come from cell and animal studies. For very high triglyceride levels the cited sources make no statement.

Common follow-up questions

There is no fixed point in time. In an umbrella review with updated meta-analysis (72 trials), lipid improvements were greater with a duration of at least 8 weeks, although results differed widely between studies (Unhapipatpong et al., 2025) DOI. In a study in fatty liver disease (NAFLD), triglycerides were lower after 8 weeks of 1,000 mg curcumin per day than at baseline (Panahi et al., 2016) DOI.

This is a medical decision; you should not stop or swap medication on your own. In a randomized trial in type 2 diabetes (60 people, 3 months, added to glimepiride), both fenofibrate (160 mg) and curcumin (1,100 mg) lowered triglycerides compared with placebo, fenofibrate at a stronger significance level (p < 0.001 vs p < 0.05) (Nada et al., 2025) DOI. A meta-analysis found an average triglyceride reduction of about 13 mg/dL, with very heterogeneous studies (Unhapipatpong et al., 2025) DOI. An equivalent replacement is therefore not shown.

Studies used very different amounts, for example 1,000 mg curcumin per day for 8 weeks in NAFLD (Panahi et al., 2016) DOI or 1,100 mg per day for 3 months in type 2 diabetes (Nada et al., 2025) DOI. A meta-analysis considers dose, dosage form and dosing frequency still unresolved (Qin et al., 2017) DOI. These are study doses, not a recommendation; discuss your dose with your doctor.

Want to dive deeper into the subject? Continue here:

Bioavailability: Understand the mechanisms of absorption and why bioavailable formulations are decisive.
Safety check: The full safety profile and important information on side effects and interactions.
Effects guide: A broad overview of the therapeutic application areas and all the benefits of curcumin.

References

[1] Alberti, K. G. M. M. et al. (2009). Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. DOI: 10.1161/CIRCULATIONAHA.109.192644
[2] Shao, W. et al. (2012). Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE. DOI: 10.1371/journal.pone.0028784
[3] Jang, E.-M. et al. (2008). Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism. DOI: 10.1016/j.metabol.2008.06.014
[4] Kang, O.-H. et al. (2013). Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. European Review for Medical and Pharmacological Sciences. PMID: 24142602
[5] Dehzad, M. J. et al. (2023). Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. DOI: 10.1016/j.ctim.2023.102955
[6] Ebrahimzadeh, A. et al. (2024). Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized clinical trials. Complementary Therapies in Medicine. DOI: 10.1016/j.ctim.2024.103025
[7] Malik, A. S. & Malik, M. (2024). Effects of curcumin in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Canadian Liver Journal. DOI: 10.3138/canlivj-2023-0022
[8] Mohammadi, A. et al. (2013). Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy Research. DOI: 10.1002/ptr.4715
[9] DiSilvestro, R. A. et al. (2012). Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutrition Journal. DOI: 10.1186/1475-2891-11-79
[10] Azhdari, M. et al. (2019). Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. DOI: 10.1002/ptr.6323
[11] Qiu, L. et al. (2023). Effects of dietary polyphenol curcumin supplementation on metabolic, inflammatory, and oxidative stress indices in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. DOI: 10.3389/fendo.2023.1216708

Meta-analyses in metabolic syndrome report partly better fasting glucose, HDL and diastolic blood pressure with curcumin; for triglycerides and waist circumference the results are inconsistent [4, 5]. Curcumin does not replace medical treatment.

In short

Meta-analyses: partly better fasting glucose, HDL and diastolic blood pressure
Triglycerides and waist circumference: the meta-analyses contradict each other
Weight and BMI: lower in one meta-analysis
High heterogeneity; not a replacement for medical treatment

What's behind it

The metabolic syndrome is a cluster of risk factors for cardiovascular disease and type 2 diabetes: raised blood pressure, raised triglycerides, low HDL, raised fasting glucose and central obesity. Three of five abnormal findings are enough for the diagnosis [1]. Evidence on curcumin's mechanisms comes from animal studies: in mice on a high-fat diet it attenuated weight and fat gain and the development of insulin resistance [2]. A review describes that curcumin modulates cytokines and transcription factors, but that its oral bioavailability is limited [3].

What the sources show

Meta-analyses in metabolic syndrome. An analysis of 7 RCTs found better values for fasting glucose, triglycerides, HDL and diastolic blood pressure; waist circumference and systolic blood pressure did not change significantly [4]. A more recent one with 13 RCTs (785 participants, 4–12 weeks) instead found a smaller waist circumference, lower fasting glucose, lower diastolic blood pressure, higher HDL and lower TNF-α and CRP. Triglycerides, systolic blood pressure, IL-6 and hsCRP did not change significantly; heterogeneity was partly high [5]. For triglycerides and waist circumference the two analyses thus contradict each other.

Weight. In 18 studies with 1,645 people with metabolic syndrome and related disorders, BMI, body weight, waist-to-hip ratio and leptin were lower with curcumin. Daily doses ranged from 70 to 2,400 mg, duration from 4 to 36 weeks [6].

Broad overview. A meta-analysis of 103 RCTs (7,216 participants, curcumin versus placebo, 42 outcomes) rates the evidence as high for fasting blood sugar, CRP, HDL and body weight, and as moderate for waist circumference, BMI, insulin and HOMA-IR. For many other outcomes it is low or very low; the authors point to methodological limitations of the studies [7].

Individual study. In 80 overweight people with borderline fasting glucose (not explicitly with metabolic syndrome), after 8 weeks on 800 mg of a phytosome product (200 mg curcumin), fasting insulin, triglycerides, liver values and fatty liver index were lower than on placebo [8].

What this means in practice

The studies differ greatly in product, dose (70–2,400 mg/day) and duration; no dosing recommendation can be derived from them. The cited analyses compare curcumin with placebo or control groups, not with lifestyle programmes or medication. They are therefore no evidence that curcumin could replace these. If you want to take curcumin, discuss it with your doctor. More at safety and side effects.

Limits of the statement

The results are heterogeneous and partly contradictory, and many studies are small and short. Depending on the outcome, the evidence ranges from high to very low [7]. Statements for people without risk factors cannot be derived from these sources.

Common follow-up questions

No, there is no evidence for that. Meta-analyses of randomized trials in metabolic syndrome show changes in individual markers only: in a pooled analysis of 7 trials, fasting glucose, triglycerides, HDL cholesterol and diastolic blood pressure improved, but waist circumference and systolic blood pressure did not (Azhdari et al., 2019) DOI. A pooled analysis of 13 trials (785 participants, 4–12 weeks) found no significant change in triglycerides; the authors call the evidence limited and heterogeneous (Qiu et al., 2023) DOI. Curcumin does not replace medical treatment.

This cannot be said across the board. Studies on metabolic syndrome lasted 4 to 12 weeks: in a meta-analysis of 13 randomized trials (785 participants), waist circumference, fasting blood glucose, HDL cholesterol and diastolic blood pressure were on average better in the curcumin groups, triglycerides and systolic blood pressure were not (Qiu et al., 2023) DOI. In a 12-week study of 88 people, triglycerides and total and LDL cholesterol fell while blood glucose remained unchanged (Sangouni et al., 2022) DOI. The evidence is limited and inconsistent.

There is no dose recommendation; the studies differ widely. Examples described are 1 g of curcuminoids plus 10 mg piperine daily for 8 weeks in 117 people with metabolic syndrome (Panahi et al., 2015) DOI and 200 mg of curcumin daily for 12 weeks in 88 people with metabolic syndrome (Sangouni et al., 2022) DOI. Seek medical advice on questions about supplements.

Want to dive deeper into the subject? Continue here:

Bioavailability: Understand the mechanisms of absorption and why bioavailable formulations are decisive.
Safety check: The full safety profile and important information on side effects and interactions.
Effects guide: A broad overview of the therapeutic application areas and all the benefits of curcumin.

References

[1] Alberti, K. G. M. M. et al. (2009). Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. DOI: 10.1161/CIRCULATIONAHA.109.192644
[2] Shao, W. et al. (2012). Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE. DOI: 10.1371/journal.pone.0028784
[3] Ghosh, S. et al. (2015). The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food and Chemical Toxicology. DOI: 10.1016/j.fct.2015.05.022
[4] Azhdari, M. et al. (2019). Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. DOI: 10.1002/ptr.6323
[5] Qiu, L. et al. (2023). Effects of dietary polyphenol curcumin supplementation on metabolic, inflammatory, and oxidative stress indices in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. DOI: 10.3389/fendo.2023.1216708
[6] Akbari, M. et al. (2019). The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. DOI: 10.3389/fphar.2019.00649
[7] Jafari, A. et al. (2024). Curcumin on human health: a comprehensive systematic review and meta-analysis of 103 randomized controlled trials. Phytotherapy Research. DOI: 10.1002/ptr.8340
[8] Cicero, A. F. G. et al. (2020). Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. European Journal of Nutrition. DOI: 10.1007/s00394-019-01916-7

Blood Sugar & Metabolic Health

Turmeric and type 2 diabetes: what do studies show?

What's behind it

What the sources show

What this means in practice

Limits of the statement

Common follow-up questions

Can curcumin replace blood-sugar-lowering medications or insulin?

How long did it take for effects to show in studies?

Which dose was used in studies?

Has curcumin been studied in type 1 diabetes?

By how much did curcumin lower fasting blood sugar in studies?

Further reading

References

Turmeric and insulin resistance: what do studies show?

What's behind it

What the sources show

What this means in practice

Limits of the statement

Common follow-up questions

Can curcumin replace tablets or insulin?

Can I inject less insulin with curcumin?

How long did it take for something to show in studies?

What about severe insulin resistance?

Does curcumin help with type 1 diabetes?

Further reading

References

Turmeric and fatty liver?

What's behind it

What the sources show

What this means in practice

Limits of the statement

Common follow-up questions

Has curcumin been studied in liver cirrhosis?

How long until liver improvement?

Which dosage is recommended for fatty liver?

Read more

References

Turmeric against triglycerides?

What's behind it

What the sources show

What this means in practice

Limits of the statement

Common follow-up questions

How quickly does curcumin lower triglycerides?

Can I take curcumin instead of fibrates?

Which dosage is recommended for elevated triglycerides?

Read more

References

Turmeric for metabolic syndrome?

What's behind it

What the sources show

What this means in practice

Limits of the statement

Common follow-up questions

Can curcumin cure metabolic syndrome?

How long until improvement?

Which dose is recommended for metabolic syndrome?

Read more

References